Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05886660 · ClinicalTrials.gov registry record · Phase 2
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
A Phase 2 study of Motion Sickness and Motion Sickness, Space, sponsored by Repurposed Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05886660: Recruiting Phase 2 study of Motion Sickness and Motion Sickness, Space, sponsored by Repurposed Therapeutics.
NCT05886660 is a Phase 2 study of Motion Sickness and Motion Sickness, Space that is actively recruiting participants, run by Repurposed Therapeutics. The registered enrollment target is 30 participants, below the 150-participant average among 6 other Motion Sickness trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05886660, a Phase 2 study of Motion Sickness and Motion Sickness, Space, is actively recruiting participants, sponsored by Repurposed Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary specific aim is to evaluate the use of intranasal scopolamine gel and sensory augmentation as an integrated countermeasure to mitigate motion sickness and enhance sensorimotor performance. The proposed intranasal scopolamine gel formulation (Defender Pharmaceuticals, Inc.) offers a safe non-invasive method to self-administer with a rapid onset of action. This study involves a comparison of motion sickness outcome measures when administering intranasal scopolamine gel versus placebo (Aim 1a), and then when administering intranasal scopolamine gel versus placebo with a sensory augmentation belt (Aim 1b).
Conditions Studied
Interventions
- DRUG DPI-386 Nasal Gel
- DRUG Placebo Nasal Gel
Study Locations (1)
Texas
- NASA Johnson Space Center Neuroscience Laboratory - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-01-21 |
| Est. Completion | 2024-09 |
| Phase | Phase 2 |
What NCT05886660 shows while recruiting
NCT05886660 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 150-participant average among 6 other Motion Sickness trials with a reported enrollment target (80% lower).
The record links to 3 conditions, with Motion Sickness appearing as the primary indexed condition, and to 2 interventions - of which DPI-386 Nasal Gel is the first listed.
NCT05886660 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05886660 about?
NCT05886660 is a clinical study titled "Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance". The primary specific aim is to evaluate the use of intranasal scopolamine gel and sensory augmentation as an integrated countermeasure to mitigate motion sickness and enhance sensorimotor performance. The proposed intranasal scopolamine gel formulation (Defender Pharmaceuticals, Inc.) offers a safe ...
What is the current status of trial NCT05886660?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-01-21. Estimated completion is 2024-09.
What conditions does trial NCT05886660 study?
This clinical trial studies the following conditions: Motion Sickness, Motion Sickness, Space, Sea Sickness.
What interventions are being tested in trial NCT05886660?
The interventions under investigation include: DPI-386 Nasal Gel (DRUG), Placebo Nasal Gel (DRUG).
Who is sponsoring clinical trial NCT05886660?
This trial is sponsored by Repurposed Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05886660 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Motion Sickness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
StableEyes With Active Neurofeedback
RECRUITING · NA
-
Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation
RECRUITING · NA
-
Three-Axis Wearable Adaptive Vestibular Stimulator
ACTIVE NOT RECRUITING · NA
-
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
ACTIVE NOT RECRUITING · Phase 3
-
Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
COMPLETED
-
Nebulizer Delivery of Intranasal Scopolamine
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI